CareRx (CRRX) Aktievy
CareRx Corporation, tillsammans med sina dotterbolag, tillhandahåller apotekstjänster till äldreboenden och andra vårdinrättningar i Kanada. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 3/6 |
Belöningar
Riskanalys
CRRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CareRx Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | CA$3.70 |
| 52 veckors högsta | CA$4.00 |
| 52 veckors lägsta | CA$2.51 |
| Beta | 0.66 |
| 1 månads förändring | -1.20% |
| 3 månaders förändring | -4.15% |
| 1 års förändring | 32.14% |
| 3 års förändring | 64.44% |
| 5 års förändring | -38.74% |
| Förändring sedan börsintroduktionen | 19.35% |
Senaste nyheter och uppdateringar
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Recent updates
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Is CareRx (TSE:CRRX) A Risky Investment?
Sep 11
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
Feb 11CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Oct 03Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Aug 11Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Apr 22Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
Mar 17CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Oct 19What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
Aug 22CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Sep 22These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively
May 14Aktieägarnas avkastning
| CRRX | CA Consumer Retailing | CA Marknad | |
|---|---|---|---|
| 7D | -0.3% | 1.5% | 0.3% |
| 1Y | 32.1% | 8.4% | 36.6% |
Avkastning vs industri: CRRX översteg Canadian Consumer Retailing branschen som gav 8.4 % under det senaste året.
Avkastning vs Marknaden: CRRX presterade sämre än Canadian marknaden som gav 36.6 % under det senaste året.
Prisvolatilitet
| CRRX volatility | |
|---|---|
| CRRX Average Weekly Movement | 3.2% |
| Consumer Retailing Industry Average Movement | 3.5% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 4.0% |
Stabil aktiekurs: CRRX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Canadian.
Volatilitet över tid: CRRX s veckovolatilitet ( 3% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2001 | 1,483 | Puneet Khanna | www.carerx.ca |
CareRx Corporation, tillsammans med sina dotterbolag, tillhandahåller apotekstjänster till äldreboenden och andra vårdinrättningar i Kanada. Företaget erbjuder tjänster inom läkemedelshantering, teknik och program. Kunderna är långtidsvårdhem, ålderdomshem, serviceboenden och gruppboenden.
CareRx Corporation Sammanfattning av grunderna
| CRRX grundläggande statistik | |
|---|---|
| Börsvärde | CA$230.95m |
| Vinst(TTM) | CA$26.13m |
| Intäkter(TTM) | CA$370.24m |
Är CRRX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CRRX resultaträkning (TTM) | |
|---|---|
| Intäkter | CA$370.24m |
| Kostnad för intäkter | CA$259.28m |
| Bruttovinst | CA$110.96m |
| Övriga kostnader | CA$84.84m |
| Intäkter | CA$26.13m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 06, 2026
| Vinst per aktie (EPS) | 0.41 |
| Bruttomarginal | 29.97% |
| Nettovinstmarginal | 7.06% |
| Skuld/egenkapitalförhållande | 37.5% |
Hur har CRRX utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 14:05 |
| Aktiekurs vid dagens slut | 2026/04/30 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
CareRx Corporation bevakas av 11 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |